Understanding how a specific receptor affects heart health
Elucidating the Role of Death Receptor 5 in the Heart
['FUNDING_R01'] · UNIVERSITY OF MISSOURI-COLUMBIA · NIH-11080758
This study is looking at how a specific protein called DR5 affects heart health and could help protect heart cells, with the hope of finding new treatments for people with heart failure.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MISSOURI-COLUMBIA (nih funded) |
| Locations | 1 site (COLUMBIA, UNITED STATES) |
| Trial ID | NIH-11080758 on ClinicalTrials.gov |
What this research studies
This research investigates the role of death receptor 5 (DR5) in heart function and its potential impact on heart failure. The study focuses on how DR5 signaling influences the survival and growth of heart muscle cells (cardiomyocytes) using pharmacological agents. By examining the effects of DR5 activation, the research aims to uncover new mechanisms that could protect the heart from damage and improve its function. The findings could lead to novel therapeutic strategies for patients with heart failure.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with heart failure or those at high risk for developing heart failure.
Not a fit: Patients with non-cardiac related health issues or those without heart failure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve heart function and survival for patients with heart failure.
How similar studies have performed: While the role of DR5 in cancer has been well-studied, this investigation into its function in heart health is novel and has not been extensively tested.
Where this research is happening
COLUMBIA, UNITED STATES
- UNIVERSITY OF MISSOURI-COLUMBIA — COLUMBIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GRISANTI, LAUREL ANN — UNIVERSITY OF MISSOURI-COLUMBIA
- Study coordinator: GRISANTI, LAUREL ANN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: cancer cell